ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 58.8 Cr.
- Current Price ₹ 45.0
- High / Low ₹ 86.1 / 44.4
- Stock P/E
- Book Value ₹ 54.5
- Dividend Yield 0.00 %
- ROCE 1.48 %
- ROE -10.6 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.83 times its book value
Cons
- Company has low interest coverage ratio.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 184 days.
- Working capital days have increased from 128 days to 199 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|
154 | 354 | 220 | 145 | 108 | |
140 | 286 | 205 | 135 | 106 | |
Operating Profit | 14 | 68 | 15 | 10 | 2 |
OPM % | 9% | 19% | 7% | 7% | 2% |
1 | 1 | 10 | -1 | 0 | |
Interest | 4 | 9 | 12 | 11 | 11 |
Depreciation | 1 | 6 | 9 | 8 | 7 |
Profit before tax | 10 | 54 | 3 | -11 | -16 |
Tax % | 31% | 25% | 110% | -5% | |
7 | 40 | -0 | -10 | -15 | |
EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -11.29 |
Dividend Payout % | 0% | 3% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -2% |
TTM: | -39% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -87% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | -55% |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 10 | 13 | 13 | 13 |
Reserves | 73 | 73 | 63 | 58 |
77 | 71 | 73 | 85 | |
130 | 119 | 92 | 86 | |
Total Liabilities | 290 | 276 | 241 | 242 |
93 | 88 | 58 | 59 | |
CWIP | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 |
198 | 188 | 183 | 183 | |
Total Assets | 290 | 276 | 241 | 242 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
25 | 26 | -9 | ||
-44 | -9 | 20 | ||
20 | -17 | -10 | ||
Net Cash Flow | 0 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 105 | 138 | 184 | |
Inventory Days | 59 | 118 | 183 | |
Days Payable | 113 | 165 | 254 | |
Cash Conversion Cycle | 51 | 91 | 113 | |
Working Capital Days | 78 | 107 | 199 | |
ROCE % | 9% | 1% |
Documents
Announcements
- Financial Results For Quarter And Half Year Ended 30.09.2024. 19h
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.11.2024
19h - Unaudited financial results for Q2 and H1 2024.
-
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015
7 Nov - Board meeting scheduled for financial results approval.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Oct - Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.09.2024.
- Scrutinizer Report And Evoting Result For AGM 30.09.2024 Of ANG Lifesciences India Limited 2 Oct
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)